• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Cytokinetics Incorporated

    11/14/25 12:18:25 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    CYTOKINETICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    23282W605

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23282W605


    1Names of Reporting Persons

    T. Rowe Price Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MARYLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    18,813,197.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    19,094,650.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    19,097,373.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.0 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CYTOKINETICS INC
    (b)Address of issuer's principal executive offices:

    350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
    Item 2. 
    (a)Name of person filing:

    T. Rowe Price Investment Management, Inc.
    (b)Address or principal business office or, if none, residence:

    1307 Point Street, Baltimore, MD 21231
    (c)Citizenship:

    Maryland
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    23282W605
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    19097373
    (b)Percent of class:

    16.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    18813197

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    19094650

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    T. Rowe Price Investment Management, Inc.
     
    Signature:Ellen York
    Name/Title:Vice President
    Date:11/14/2025
    Get the next $CYTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    12/18/2025$95.00Neutral → Buy
    Goldman
    7/30/2025Mkt Perform
    Raymond James
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    1/22/2025$80.00Buy
    Stifel
    11/8/2024$80.00Outperform
    RBC Capital Mkts
    8/13/2024$85.00 → $60.00Buy → Neutral
    Goldman
    1/24/2024$61.00 → $92.00Buy → Neutral
    UBS
    More analyst ratings

    $CYTK
    SEC Filings

    View All

    Cytokinetics Incorporated filed SEC Form 8-K: Other Events

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    12/19/25 4:01:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Other Events

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    12/12/25 8:54:21 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Leadership Update

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    11/14/25 4:05:27 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Cytokinetics

    Raymond James resumed coverage of Cytokinetics with a rating of Mkt Perform

    7/30/25 7:32:47 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Cytokinetics with a new price target

    Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00

    4/24/25 7:43:15 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Commercial Officer Callos Andrew sold $904,200 worth of shares (15,000 units at $60.28) and exercised 15,000 shares at a strike of $23.26 (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    1/5/26 4:26:59 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Callos Andrew sold $112,585 worth of shares (1,798 units at $62.62) and exercised 885 shares at a strike of $37.63, decreasing direct ownership by 2% to 50,440 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    1/2/26 6:01:33 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Callos Andrew sold $112,954 worth of shares (1,809 units at $62.44), decreasing direct ownership by 3% to 51,353 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    12/30/25 4:34:40 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 AM Pacific Time in San Francisco, CA. Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical

    1/5/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever

    12/19/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

    Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM), to improve exercise capacity and symptoms. Under the terms of its license and collaboration agreement with Cytokinetics, Sanofi has exclusive rights to develop and commerc

    12/17/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics Names Jim Daly to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi

    8/20/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Robert E. Landry to Board of Directors

    Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

    2/11/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytokinetics Incorporated

    SC 13G - CYTOKINETICS INC (0001061983) (Subject)

    11/14/24 1:28:31 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 2:21:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 9:55:17 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever

    12/19/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the third quarter of 2025. "I'm pleased that our teams continue to demonstrate strong execution and sustained momentum as we approach the PDUFA date for the aficamten NDA. Our commercial preparations have been deliberate and strategic, positioning us well

    11/5/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Third Quarter Results on November 5, 2025

    SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics' w

    10/22/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care